Department of Cellular Pathology, Royal Free Hospital, London, UK.
Department of Cellular Pathology, Royal Free Hospital, London and University College London, London, UK.
United European Gastroenterol J. 2022 Jun;10(5):451-464. doi: 10.1002/ueg2.12242. Epub 2022 May 28.
Drug-induced mucosal injury (DIMI) in the gastrointestinal tract is important to recognise, partly because cessation of the culprit agent alone may result in resolution of symptoms. An ever-growing list of medications, including newer immunotherapeutic agents and targeted therapies, can cause gastrointestinal inflammation of varying severity. However, the diagnosis of DIMI is challenging, as a single drug can induce a variety of histopathological patterns of injury including acute colitis, chronic colitis, microscopic colitis, apoptotic colopathy, and ischaemic-type colitis. An additional consideration is the potential clinical, endoscopic and histological overlap of DIMI with gastrointestinal mucosal injury secondary to other entities such as inflammatory bowel disease (IBD). We discuss DIMI of the gastrointestinal tract with an emphasis on histological patterns that mimic IBD, histological features which may distinguish the two entities, and the diagnostic role and limitations of the pathologist.
药物诱导的胃肠道黏膜损伤(DIMI)需要引起重视,部分原因是单独停用致病药物可能会使症状得到缓解。越来越多的药物,包括新型免疫治疗药物和靶向治疗药物,均可引起不同严重程度的胃肠道炎症。然而,DIMI 的诊断具有挑战性,因为一种药物可引起多种组织病理学损伤模式,包括急性结肠炎、慢性结肠炎、显微镜下结肠炎、凋亡性结肠炎和缺血性结肠炎。需要考虑的另一个因素是,与其他实体疾病(如炎症性肠病,IBD)引起的胃肠道黏膜损伤相比,药物诱导的胃肠道黏膜损伤在临床表现、内镜和组织学上可能存在重叠。我们将重点讨论胃肠道的 DIMI,包括与 IBD 相似的组织病理学模式、可能区分两者的组织学特征,以及病理学家的诊断作用和局限性。